medigraphic.com
ISSN 0001-0944 (Print)
Órgano Oficial de la Asociación Dental Mexicana

2022, Number 4

<< Back

Rev ADM 2022; 79 (4)

Osteonecrosis of the jaws: drug reaction.

Rodríguez AT, García GFG, Salinas NA

Language: Spanish
References: 40
Page: 232-238
PDF size: 236.87 Kb.


ABSTRACT

Medication-related osteonecrosis of the jaw (MRONJ), secondary to the consumption of antiresorptive and antiangiogenic drugs is an oral pathology that affects the functioning of the human body, not only at the oral level, but also decreasing their quality of life and increasing their morbidity. MRONJ is defined as the presence of exposed necrotic bone that can be explored through a fistula in the maxillofacial territory, which is maintained for a minimum period of eight weeks. Antiresorptive and antiangiogenic drugs are indicated for patients with osteometabolic pathologies, cancer, among others. For the same reasons, the importance of maintaining a close relationship between the treating physician, dentist and patient. The purpose of this article is to establish a clinical guide for basic oral care and define the functions of the treating physician, dental surgeon and maxillofacial surgeon through a bibliographic review; in order to create a preventive proposal for the treatment of these patients.


REFERENCES

  1. Foncea C, Bischhoffhausen K, Teuber C, Ramirez H, Goñi I, Sánchez C et al. Osteonecrosis de los maxilares asociada a medicamentos: revisión de la literatura y propuesta para la prevención y manejo. Rev Med Chile. 2020; 148: 983-991.

  2. Rasmusson L, Abtahi J. Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent. 2014; 2014: 471035.

  3. Figueroa L, Alvarado B, Gallardo P, Cifuentes J. Sinusitis maxilar por osteonecrosis asociada a bisfosfonatos en pacientes con cáncer de mama: serie de casos. Int J Odontostomat. 2015; 9(3): 449-455.

  4. Yarom N, Shapiro C, Peterson D, Van Poznak C, Bohlke K, Ruggiero SL et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019; 37 (25): 2270-2290.

  5. Sigua E, Costa R, Ramos A, Alvarez N, Albergaria JR. Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent. 2014; 2014: 1-5.

  6. Picardo SN, Rodriguez S, Rey E. Osteonecrosis maxilar asociada a bifosfonatos en pacientes osteoporóticos. Rev Esp Cirug Oral y Maxilofac. 2015; 37 (2): 103-107.

  7. Pelaz A, Junquera L, Gallego L, Garcia-Consuegra L, Garcia L, Cutilli T et al. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp. 2015; 66 (3): 139-147.

  8. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020; 12 (1): 30.

  9. Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int. 2018; 2018: 2684924.

  10. Shannon J, Shannon J, Modelevsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc. 2011; 59 (12): 2350-2355.

  11. Crépin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. Eur J Clin Pharmacol. 2010; 66 (6): 547-554.

  12. Herrera S, Arehana C, Chrivella L, Oxmerari J. Bolsa adiposa de bichat: fuente alternativa de células madres, uso quirúrgico e ilustración de técnica-revisión de literatura. Act Odontol Venezol. 2019.

  13. Bermudez E. Revisión y puesta al día sobre patología odontológica y bifosfonatos en la práctica clínica diaria. Actual Med. 2014; 99: 92-95.

  14. Mollica V, Nuvola G, Tassinari E, Concetta M, Marchetti A, Rosellini M. Massari F. Bone targeting agents in patients with prostate cancer: general toxicities and osteonecrosis of the jaw. Curr Oncol. 2022; 29: 1709-1722.

  15. Huang YF, Chang CT, Muo CH, Shen YF, Zong Wu C. Impact of bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental extraction: a population-based cohort study. PLoS One. 2015; 10 (4): e0120756.

  16. Gonzalez F, Partida E, Utera S, Diaz M, Medrano K. Tratamiento de la osteonecrosis de los maxilares. Casos clínicos y revisión bibliográfica. Rev Mex Cir Bucal Maxilofac 2015; 11 (3): 100-109.

  17. Allen M, Burr D. The pathogenesis of bisphosphonate- related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009; 67 (5 Suppl): 61-70.

  18. Huang YF, Chang CT, Hsin C, Tsai C, Shen YF, Wu CZ. Impact of bisphosphonate-related osteonecrosis of the jaw on osteoporotic patients after dental extraction: a population-based cohort study. PLoS One. 2015; 10 (4): 1-13.

  19. Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008; 121 (6): 475-483.

  20. Wei X, Pushalkar S, Estilo C, Wong C, Farooki A, Fornier M et al. Molecular profiling of oral microbiota in jawbone samples of bisphosphonate-related osteonecrosis of the jaw. Oral Dis. 2012; 18 (6): 602-612.

  21. Ruggiero S, Dodson T, Assael L, Landesberg R. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. Aust Endod J. 2009; 35: 119-130.

  22. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.

  23. Dello Russo NM, Jeffcoat MK, Marx RE, Fugazzotto P. Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis. Int J Oral Maxillofac Implants. 2007 Jan-Feb;22(1):146-53. PMID: 17340909.

  24. Aghaloo T, Dry S, Mallaya S, Tetradis S. Stage 0 Osteonecrosis of the Jaw (ONJ) in a patient on denosumab. J Oral Maxillofac Surg. 2014; 72 (4): 702-716.

  25. Coskun BI, Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect. ISRN Rheumatol. 2013; 2013: 215034.

  26. Fernandez O. La osteonecrosis asociada al tratamiento con bisfosfonatos en osteoporosis primaria. Revisión de la literatura. An Sist Navar. 2013; 36 (1): 87-97.

  27. Mauceri R, Panzarella V, Maniscalo L, Bedogni A, Licata ME, Albanese A et al. Conservative surgical treatment of bisphosphonate-related osteonecrosis of the jaw with Er,Cr:YSGG laser and platelet-rich plasma: a longitudinal study. Biomed Res Int. 2018; 2018: 3982540.

  28. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S et al. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent. 2014; 2014: 107690.

  29. Montebugloni L, Felicetti L, Bartolomeo D, Pizzigallo A, Pelliccioni G, Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Edod. 2007; 104: 473-477.

  30. Cardoso CL, Barros CA, Curra C, Fernandes LM, Franzolin SO, Júnior JS et al. Radiographic findings in patients with medication-related osteonecrosis of the jaw. Int J Dent. 2017; 2017: 3190301.

  31. Giribone J, Catagnetto P. Osteonecrosis de los maxilares inducida por bifosfonatos; lo que el odontólogo debe saber hoy: pautas y protocolos. Odontoestomatología. 2013; 15 (21): 45-58.

  32. Fernandez R, Joya E, Villegas C, Muñoz S, Manrique R. Knowledge, attitudes, and practices of dentists in Colombia regarding bisphosphonate-induced osteonecrosis of the jaws. CES Odontología. 2020; 33 (1): 14-21.

  33. Palencia A, Porte JP, Martinez J, Guerra D. Efectividad del uso de la bolsa adiposa de Bichat para la reconstrucción de defectos en el paladar. Reporte de un caso. Revista ADM. 2017; 74 (3): 159-162.

  34. Capote C, Mogensen M, Sanchez MC, Cedeño J. Consideraciones en el tratamiento odontológico de pacientes en terapia con bifosfonatos. Act Odontol Venezol. 2011; 49 (4).

  35. Furnas C, Benningfield B, Norris M. The unintended oral benefits of bisphosphonates in relation to osteoporosis. Student Focus, 2019; 17-18.

  36. Medina A. Alternativas de tratamiento para la osteonecrosis de los maxilares asociada a bisfosfonatos. Av Odontoestomatol. 2010; 26 (3): 153-159.

  37. Pelaz A, Junquera L, Gallego L, Garcia L, Garcia L, Cutilli T et al. Epidemiology, pharmacology and clinical characterization of bisphosphonate-related osteonecrosis of the jaw. A retrospective study of 70 cases. Acta Otorrinolaringol Esp. 2015; 66 (3): 139-147.

  38. Scaf de Molon R, Cheong S, Bezouglaia O, Dry S, Pirih F, Cirelli J et al. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: A novel ONJ mouse model. Bone. 2014; 68: 11-19.

  39. Ramirez J, Prise J, Armas A, Agurto J. Uso de bolsa adiposa de Bichat pediculada como recurso para el cierre de comunicaciones y fístulas bucoantrales: informe de caso. Odontol Vit. 2020; 33: 7-14.

  40. Figueroa L, Alvarado B, Gallardo P, Saenz F. Osteonecrosis maxilar con compromiso sinusal asociada a bifosfonatos endovenosos: reporte de tres casos. Act Odontol Venezol. 2015; 1 (53): 1-7.




2020     |     www.medigraphic.com